Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “sell” rating reissued by equities research analysts at Wells Fargo & Company in a research note issued on Friday, July 14th.
Several other equities analysts have also recently weighed in on the stock. Stifel Nicolaus reaffirmed a “buy” rating and issued a $35.00 price target (down previously from $45.00) on shares of Valeant Pharmaceuticals International in a research report on Wednesday, May 17th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $18.00 price target (down previously from $21.00) on shares of Valeant Pharmaceuticals International in a research report on Thursday, March 23rd. Deutsche Bank AG dropped their price target on shares of Valeant Pharmaceuticals International from $19.00 to $18.00 and set a “hold” rating on the stock in a research report on Wednesday, April 19th. Piper Jaffray Companies reiterated an “outperform” rating and issued a $10.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Friday, April 14th. Finally, Scotiabank increased their price objective on shares of Valeant Pharmaceuticals International from $12.00 to $14.00 and gave the company a “sector perform” rating in a research note on Wednesday, May 10th. Four analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $17.31.
Shares of Valeant Pharmaceuticals International (NYSE VRX) opened at 13.89 on Friday. Valeant Pharmaceuticals International has a one year low of $8.31 and a one year high of $32.74. The stock has a 50 day moving average price of $16.57 and a 200-day moving average price of $13.38. The company’s market capitalization is $4.83 billion.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The company had revenue of $2.23 billion for the quarter, compared to analysts’ expectations of $2.23 billion. During the same quarter in the prior year, the firm earned ($0.88) EPS. The business’s revenue was down 7.7% on a year-over-year basis. Equities research analysts predict that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Stock Rating Reaffirmed by Wells Fargo & Company” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.com-unik.info/2017/08/12/valeant-pharmaceuticals-international-inc-nysevrx-given-sell-rating-at-wells-fargo-company-updated-updated-updated.html.
A number of large investors have recently bought and sold shares of VRX. Morgan Stanley raised its stake in Valeant Pharmaceuticals International by 48.2% in the first quarter. Morgan Stanley now owns 2,777,063 shares of the specialty pharmaceutical company’s stock valued at $30,631,000 after buying an additional 903,256 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its position in shares of Valeant Pharmaceuticals International by 61.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 41,414 shares of the specialty pharmaceutical company’s stock valued at $457,000 after buying an additional 15,719 shares in the last quarter. Gabelli Funds LLC purchased a new position in shares of Valeant Pharmaceuticals International during the first quarter valued at about $331,000. Searle & CO. purchased a new position in shares of Valeant Pharmaceuticals International during the fourth quarter valued at about $972,000. Finally, Bogle Investment Management L P DE purchased a new position in shares of Valeant Pharmaceuticals International during the first quarter valued at about $11,223,000. 51.14% of the stock is currently owned by institutional investors and hedge funds.
Valeant Pharmaceuticals International Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
What are top analysts saying about Valeant Pharmaceuticals International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Valeant Pharmaceuticals International Inc. and related companies.